Table 1 Demographic and clinical characteristics of participants enrolled in the acquired HIV drug resistance study
|  |  | All participant (n = 143) | Resistance data (n = 115) | No resistance data (n = 28) |
|---|---|---|---|---|
Sex, female | n (%) | 76 (53.1) | 62 (53.9) | 14 (50.0) |
Age | Median (IQR) | 39 (31–46) | 38 (30–46) | 44 (36–50) |
Current or previous TB | n (%) | 64 (44.8) | 56 (48.7) | 8 (28.6) |
Latest HIV RNA, log10 copies/mL | Median (IQR) | 4.2 (3.4–4.8) | 4.3 (3.6–4.9) | 3.2 (3.1–3.6) |
Latest CD4 + cell count | Median (IQR) | 301 (138–429) | 270 (136–394) | 529 (199–728) |
ART regimen | Â | Â | Â | Â |
First-line | n (%) | 91 (63.6) | 70 (60.9) | 21 (75.0) |
 TDF + FTC +EFV | n (%) | 88 (61.5) | 68 (59.1) | 20 (71.4) |
 ABC + 3TC + EFV | n (%) | 3 (2.1) | 2 (1.7) | 1 (3.6) |
Second-line | n (%) | 51 (35.7) | 44 (38.3) | 7 (14.3) |
 AZT + 3TC + LPV/r | n (%) | 34 (23.8) | 30 (26.1) | 4 (14.3) |
 TDF + FTC + LPV/r | n (%) | 11 (7.7) | 8 (7.0) | 3 (10.7) |
 ABC + 3TC + LPV/r | n (%) | 5 (3.5) | 5 (4.3) | 0 |
 AZT + 3TC + ATV/r | n (%) | 1 (0.7) | 1 (0.9) | 0 |
Third-line | n (%) | 1 (0.7) | 1 (0.9) | 0 |
 TDF + FTC + DTG + DRV/r + ETR | n (%) | 1 (0.7) | 1 (0.9) | 0 |